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Objective: To examine incidence rates and antecedents of mild cognitive impairment (MCI) and Alzheimer’s disease (AD)
among diverse elders without dementia at the initial visit, and to examine the characteristics of elders with MCI who reverted
to normal on follow-up examination.
Methods: A total of 2,364 Caribbean Hispanic, black, or non-Hispanic white subjects, aged 65 or older, who were free of
dementia at initial evaluation were followed up every 18 to 24 months. Incidence rate of MCI and AD was determined by
examination of neurological, medical, psychiatric, and neuropsychological function.
Results: Over 10,517 person-years, 21% of normal elderly subjects progressed to MCI (annual incidence rate, 5.1%; 95%
confidence interval, 4.6–5.6%). Of those with MCI initially, 21.8% were subsequently diagnosed with AD (annual incidence
rate, 5.4%; 95% confidence interval, 4.7–6.3%), 47% remained unchanged, and 31% reverted to normal. Those with MCI
were 2.8 times more likely to experience development of AD than normal elderly subjects. MCI with impairment in memory
and at least one other cognitive domain was associated with greatest risk for progression to AD and was also least likely to revert
to normal at follow-up. Consistent diagnosis of MCI or incident probable or possible AD was 60% sensitive and 94% specific
for the pathological diagnosis of AD.
Interpretation: Impaired memory and language were useful predictors of transition to AD. Reversion to normal from MCI was
frequent, but those with impairment in more than one cognitive domain were more likely to progress or remain impaired than
those with single-domain impairment. Clinical diagnosis of MCI does not always predict AD neuropathology.
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The term mild cognitive impairment (MCI) describes
the transitional state between normal aging and Alzhei-
mer’s disease (AD)1–3 or dementia.4 Implementation of
the criteria for MCI, as well as determination of the
rates of progression from MCI to AD or dementia, has
been an area of great interest, in part because identify-
ing the earliest signs of dementia will be crucial for
interventions to prevent or slow progression of decline
in AD and for research on AD and other dementias.5
The prevalence of MCI, as well as progression rates
to AD or dementia, vary depending on multiple factors
such as implementation of MCI criteria, recruitment
source, age at the initial assessment, and length of
follow-up. Annual progression from MCI to dementia
ranges from 12 to 17%1,3,6 in clinic-based studies,
whereas lower progression rates have been observed in
population- or community-based studies (4–15%7–13
per year). Furthermore, in population-based studies,
there appears to be more frequent occurrence of
“reversion to normal” among elderly people with
MCI than in clinical cohorts, ranging from 14 to
40%.8,9,11,13,14
In addition to the type of cohort, the other key
methodological factors differing across studies of MCI
include: (1) whether MCI diagnoses are assigned on a
case-by-case basis in a consensus conference of expert
clinicians or assigned purely objectively using neuro-
psychological, functional, and medical data; (2)
whether the diagnoses were made based on data col-
lected before formal criteria for MCI were published,
and thus may not be entirely suitable for the applica-
tion of Peterson criteria for MCI; (3) the extent to
which nondemented older subjects with memory defi-
cits are distinguished from those with cognitive deficits
in nonmemory domains; (4) the extent to which those
with isolated deficits in one cognitive domain are dis-
tinguished from those with impairment in multiple
cognitive domains; (5) the test score “cutoff” (and thus
the extent of impairment) used to define cognitive im-
pairment; (6) the use of norms that adjust for age and
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other background factors such as years of school, sex,
and race/ethnicity; (7) the extent to which subjective
memory complaints are considered as a requirement
for the diagnosis of MCI; (8) whether intact functional
capacity was required for a diagnosis of MCI; and fi-
nally, (9) whether follow-up diagnosis is made with the
knowledge of prior diagnostic status.
Few longitudinal studies of MCI have been con-
ducted among elderly people from diverse racial or eth-
nic groups,14 or from those from other linguistic or
educational8 backgrounds. Progression rates to AD
may differ among ethnically and educationally diverse
elderly individuals with MCI because the cognitive
tests used to classify “objective” cognitive impairment
have poor specificity in these groups.15,16 Furthermore,
compared with non-Hispanic white individuals, black
and Hispanic individuals are more likely to have hy-
pertension and diabetes,17,18 and the impact of these
conditions on the incidence rates of MCI and on the
progression to dementia from MCI is unknown.
In this study, we determined the incidence rates of
MCI within a large population-based cohort of ethni-
cally, linguistically, and educationally diverse elders
without dementia or cognitive impairment at the be-
ginning of the study. We also compared the incidence
rates of AD and dementia among elders with or with-
out MCI at baseline, and compared rates of progres-
sion across MCI subtypes and determined the anteced-
ents for progression. We also examined the proportion
and characteristics of elderly subjects with MCI who
reverted to normal on follow-up examination and com-
pared these data with subjects who still had MCI or
progressed to AD at follow-up. Among a small sub-
sample of elders who died and donated brain tissue, we
performed a preliminary exploration of the relation of
MCI classification to presence of AD neuropathology
and final neuropathological diagnoses.
Subjects and Methods
The Columbia University Institutional Review Board ap-
proved this project. All individuals discussed the study with a
trained research assistant and provided written informed con-
sent before their baseline visit.
Sampling Plan and Participants
Participants were Medicare recipients aged 65 or older resid-
ing in three contiguous census tracts in Northern Manhat-
tan, New York, in the neighborhoods of Washington/Ham-
ilton Heights and Inwood who were asked to participate in a
longitudinal study of aging, cognitive function, and demen-
tia. The population from which participants were drawn was
composed of individuals from several countries of origin rep-
resenting three broadly defined ethnic categories (ie, Carib-
bean Hispanic, black, and non-Hispanic white of European
ancestry). Participants were excluded if they did not speak
English or Spanish. The study combined longitudinal data
from two recruitment efforts in this community, one begin-
ning in 1992 and the other in 1999. The sampling strategies
and recruitment outcomes of these two cohorts are detailed
in prior publications.19–21 Reevaluations occurred during
follow-up waves that were spaced approximately 18 to 30
months apart. Beginning in 2002, participants in both co-
horts were asked whether they were interested in brain do-
nation.
As shown in Figure 1, combining the 1992 and 1999 co-
horts resulted in a group of 4,308 potential participants for
this study. Data were used from only those participants who
had sufficient neuropsychological, functional, medical, and
neurological information to determine the presence or ab-
sence of MCI using published criteria.19 We found that
3830 (89%) participants had sufficient data. We computed
the incidence rates for MCI and dementia in a sample ex-
cluding 615 individuals with prevalent dementia at the initial
visit and 785 elders without longitudinal data. Among the
785 subjects without longitudinal data, 38% refused further
visits, 24% died, 20% could not be located, 11% moved out
of the area, 6% could not be scheduled for a visit, and 1%
were lost for some other reason. Therefore, the “overall” rate
of follow-up in this sample was 76% including deaths. The
follow-up rate among people who were alive at the time of
follow-up was 81%. For these analyses, we further excluded
66 (2.7%) of the 2,430 participants who did not have de-
mentia at first visit and were seen for at least 1 follow-up but
had insufficient data required for a diagnosis of dementia or
MCI at any follow-up visit. Participants in this study (n 
2,364) had an average age of 75.8 years (standard deviation
[SD], 6.4) and average years of school of 10.0 years (SD,
4.8). They were significantly younger and better educated
than those excluded because of missing data or lack of
follow-up (n  1,329; 36%), whose average age was 76.6
years (SD, 6.8) and average years of school was 9.2 years
(SD, 4.4). The groups did not differ with respect to racial
composition, but there were significantly more women
Fig 1. Derivation of the sample for this study from two
community-based samples recruited in 1992 and 1999.
MCI  mild cognitive impairment.
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(68.6%) in the final sample than among those who were ex-
cluded (64.9%). Using a summary measure of medical bur-
den, we found that those who were excluded did not have
more medical illnesses than the final sample. As compared
with those in the final sample, elders without follow-up were
significantly more likely to score less than 1.5 SDs below the
demographically matched normative sample on neuropsycho-
logical composite scores assessing memory (25 vs 17%), ex-
ecutive function (21.5 vs 13%), visuospatial function (21.5
vs 17.4%), and language function (23.1 vs 17.5%). The av-
erage time between follow-up visits in the final sample was
24.3 months (SD, 6.4). Of the sample of 2,364 elders, 823
were reevaluated 1 time, 901 were reevaluated 2 times, 192
were reevaluated 3 times, 174 were reevaluated 4 times, 165
were reevaluated 6 times, 89 were reevaluated 7 times, 9
were reevaluated 8 times, and 11 were reevaluated 9 times.
Of the 2,364 participants in the study, 388 (16.4%) died
at follow-up, and an autopsy was obtained in 27 (7%) of
those who died. As compared with the full sample of 2,337
participants who were not autopsied, the autopsied partici-
pants were significantly older at the initial assessment
(76.1  6.2 vs 79.3  6.8 years; t[1, 2,362]  2.7; p 
0.008) and had more years of school (12.5  4.7 vs 9.9 
4.8 years; t[1, 2,362]  2.7; p  0.007) but did not differ
with respect to ethnic composition, sex distribution, or pro-
portion of elders who met criteria for MCI.
Assessment Procedures
RACIAL/ETHNIC GROUP.
Ethnic group was determined by self-report using the format
of the 2000 US Census.22 All subjects were first asked to
report their race (ie, American Indian/Alaska Native, Asian,
Native Hawaiian or other Pacific Islander, black or African
American, or white); then in a second question, they were
asked whether they were Hispanic.
MEDICAL AND NEUROLOGICAL EVALUATION.
At the initial visit and each follow-up examination, a physi-
cian recorded medical history and medications in a semi-
structured format. Neurological and physical examinations
were performed, including assessment of extrapyramidal signs
and functional status.
PSYCHIATRIC STATUS.
Presence of current depression was determined by asking
nine questions that correspond with Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition23 criteria for
major depressive episode. Current depressive symptoms were
assessed using 10 items from the Center for Epidemiological
Studies-Depression Scale.24,25 Presence of past major depres-
sive episodes, as well as current or past anxiety disorders, psy-
chosis, hallucinations, delusions, psychiatric hospitalizations,
psychiatric medications, and alcohol or drug dependence was
also assessed. Elderly individuals with depression or other
psychiatric disorders were not excluded from the study.
ASSESSMENT OF ACTIVITIES OF DAILY LIVING.
Items from a Disability and Functional Limitations Scale26,27
were used to elicit self or observer ratings of instrumental
activities of daily living, such as using the telephone, prepar-
ing meals, handling money, and completing chores. This in-
strument has the flexibility to be completed using informa-
tion from the participant or a collateral, who is a family
member, friend, or other person identified by the partici-
pant. A summary measure was created, compiling complaints
from six domains (using the phone, cooking, shopping, han-
dling finances, making change for purchases, and correctly
taking medications). Based on a cutoff capturing 95% of the
normative sample, participants were considered to be func-
tionally intact if they or their caregivers reported difficulty
on fewer than three of these items.
MEMORY COMPLAINTS.
Perceived difficulty with memory was assessed with 11 items
from the Disability and Functional Limitations Scale (see
earlier) and the Blessed Functional Activities Scale.28 Partic-
ipants were asked whether they had memory difficulties in
general, as well as difficulties in specific areas such as mem-
ory for names. Participants were considered to have memory
complaints if they indicated that they had problems on one
or more of the items.
NEUROPSYCHOLOGICAL BATTERY.
The neuropsychological measures used were selected to assess
cognitive functions that are typically affected in dementia
and have been shown to effectively distinguish between nor-
mal aging and dementia in this community.29 The evalua-
tion included measures of learning and memory, orientation,
abstract reasoning, language, and visuospatial ability. Specific
ability areas and tests administered include verbal list learn-
ing and memory (Selective Reminding Test30), nonverbal
memory (multiple-choice version of the Benton Visual Re-
tention Test [BVRT]31), orientation (items from the Mini-
Mental State Examination32), verbal reasoning (Similarities
subtest of the Wechsler Adult Intelligence Scale–Revised33)
nonverbal reasoning (Identities and Oddities subtest of the
Mattis Dementia Rating Scale34), naming (15-item version
of the Boston Naming Test35), letter fluency (Controlled
Word Association36), category fluency (animals, food, and
clothing, using procedures from the Boston Diagnostic
Aphasia Examination [BDAE]37), repetition (high-frequency
phrases of the BDAE37), auditory comprehension (first six
items of the Complex Ideational Material subtest of the
BDAE37), visuoconstruction (Rosen Drawing Test38), and
visuoperceptual skills (multiple-choice matching of figures
from the BVRT31). Norms for these tests in this population
were developed based on age, years of school, sex, and eth-
nicity, and were described previously.19
CONSENSUS DIAGNOSIS.
After each clinical assessment, a group of physicians and neu-
ropsychologists reviewed the functional, medical, neurologi-
cal, psychiatric, and neuropsychological data, and reached a
consensus regarding the presence or absence of dementia us-
ing Diagnostic and Statistical Manual of Mental Disorders,
Third Edition Revised criteria.39 For follow-up evaluations,
this group was shielded from the prior consensus diagnoses.
If dementia was diagnosed, the cause was determined using
published research criteria for probable and possible AD,40
vascular dementia,41 Lewy body dementia,42 and other de-
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mentias. Severity of dementia was rated using the Clinical
Dementia Rating Scale.43 Only those who were not diag-
nosed with dementia were considered for a diagnosis of
MCI.
MILD COGNITIVE IMPAIRMENT DIAGNOSTIC CRITERIA.
MCI criteria were retrospectively applied among nonde-
mented individuals after the consensus conference for each
visit. Consistent with standard criteria,2 for all subtypes of
MCI, those considered for MCI were required to have the
following characteristics: (1) a memory complaint (defined
earlier); (2) objective impairment in at least one cognitive
domain based on the average of the scores on the neuropsy-
chological measures within that domain and a 1.5 SD cutoff
using corrections for age, years of education, ethnicity, and
sex, and based on the previously established norms; (3) es-
sentially preserved activities of daily living (defined earlier);
and (4) no diagnosis of dementia at the consensus confer-
ence. A fifth criterion for amnestic MCI is “preserved general
cognitive function.” For the MCI subtypes with isolated im-
pairment in one cognitive domain, this criterion was met if
neuropsychological test scores in other cognitive domains
were not impaired. That is, cognitive criteria for MCI-
amnestic were met if elders were not impaired on the com-
posite scores for visuospatial, language, and executive func-
tion.
To cast the widest net to determine prevalence of MCI
and to determine which individuals were more likely to
progress to dementia, we expanded the original Petersen cri-
teria,1,2 which focus on memory impairment, to include mu-
tually exclusive subtypes based on cognitive features. Our
first subtype, MCI-amnestic, corresponded most closely to
the original definition that Petersen and colleagues1,2 used.
Memory impairment was defined as a score less than 1.5 SD
below demographically corrected mean on an average com-
posite measure comprising the following learning and mem-
ory measures: (1) total recall from the Selective Reminding
Test, (2) delayed free recall from the Selective Reminding
Test, and (3) recognition from the BVRT. Performance on
composite scores from all other cognitive domains (ie, exec-
utive, language, and visuospatial) was required to be within
reference limits (score had to be 1.5 SD below the demo-
graphically corrected mean). Other MCI subtypes were clas-
sified allowing for impairment in a single nonmemory do-
main if performance on composite scores from all other
cognitive domains was within norms. MCI-executive func-
tion was assigned if impairment was demonstrated on an av-
erage composite measure comprising the following measures:
(1) Letter Fluency, (2) Category Fluency, and (3) the Wech-
sler Adult Intelligence Scale–Revised Similarities subtest.
MCI-language was defined as isolated impairment on an av-
erage composite measure comprising: (1) Boston Naming
Test, (2) BDAE Repetition, and (3) BDAE Comprehension
test. MCI-visuospatial was assigned if impairment was dem-
onstrated on an average composite score comprising: (1)
Rosen Drawing and (2) BVRT matching. As described in
prior studies of MCI (Boyle, 2006 [ref. 9]; Lopez OL, Jagust
WJ, DeKosky ST, et al. Prevalence and classification of mild
cognitive impairment in the Cardiovascular Health Study
Cognition Study: part 1. Arch Neurol 2003;60:1385-1389;
Petersen, RC. Mild cognitive impairment as a diagnostic en-
tity. J Intern Med 2004;256:183-194.), cognition could also
be impaired in multiple cognitive domains. MCI-multiple
cognitive domains with memory impairment (MCI-MCDM)
was diagnosed if there was objective impairment on the
memory domain composite score and if there was impair-
ment on at least one other cognitive domain. MCI-multiple
cognitive domains without memory impairment (MCI-
MCDN) was assigned if there was impairment in two or
more of the three nonmemory domains and if the memory
domain composite score was within norms. Again, classifica-
tion into the six subtypes was mutually exclusive.
NEUROPATHOLOGY.
The brains were harvested as soon as possible after death,
weighed fresh, and processed according to an upgraded ver-
sion of a published protocol.44 In brief, each brain was di-
vided after a sagittal cut through the corpus callosum. One
half was extensively dissected, and blocks were frozen fresh
for further investigations. The other half was immersed in
buffered, 10% formalin solution and processed for thorough
neuropathological evaluation. For microscopical examination,
at least 18 standardized representative blocks were obtained;
additional blocks were selected as per the findings on gross
examination or documented symptoms. Seven-micrometer-
thick paraffin sections from all blocks were stained with
Luxol fast blue and counterstained with hematoxylin and eo-
sin for general survey. Selected sections were stained with
Bielschowsky for evaluation of axons, neuritic plaques, and
neurofibrillary and glial tangles; antibodies against -amyloid
for vascular and parenchymal deposits; phosphorylated tau
(AT8) for neuronal and glial tangles; ubiquitin for ubiquiti-
nated cytoplasmic, nuclear, or axonal aggregates; -synuclein
for Lewy bodies, Lewy neurites, and glial tangles; or other
antibodies as indicated by findings or history. The mean
number of neuritic plaques in 5 random 100 fields per
slide was recorded using Bielschowsky-stained slides or
-amyloid–labeled sections from 7 blocks.
A diagnosis of AD was assigned according to the criteria
of the Consortium to Establish a Registry for Alzheimer’s
Disease.45 The likelihood that dementia was due to the AD
changes (neuronal loss, presence of neurofibrillary tangles of
AD and of neuritic plaques) was assessed according to the
criteria proposed by The National Institute on Aging, and
Reagan Institute Working Group on Diagnostic Criteria for
the Neuropathologic Assessment of Alzheimer’s Disease.46
Furthermore, a Braak and Braak stage was assigned to reflect
the extent of involvement of the neurofibrillary tangles of
AD.47 A brain was assigned to the category of AD Lewy
body variant if there was documented dementia, neuronal
loss with neuritic plaques, and neurofibrillary tangles that oc-
curred in numbers of diagnostic significance for AD, and
with cortical and subcortical Lewy bodies. The subcortical
areas with Lewy bodies included substantia innominata,
amygdala, hypothalamus, substantia nigra pars compacta,
and nucleus ceruleus. Other causes of dementia were diag-
nosed according to standard neuropathological criteria avail-
able at the time of autopsy.
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Data Analyses
Demographic and follow-up characteristics of participants
who were classified as having MCI were compared with
those without MCI using t tests and 2 analyses. Among
those without MCI at baseline, age-specific incidence rates of
MCI were calculated within four age groups (65–69, 70–74,
75–79, 80 years), and 95% confidence intervals (CIs)
about these rates (assuming a Poisson distribution) were cal-
culated separately for the entire population, for men and
women, by ethnic group, and by years of education, split at
the median (0–11 vs 12 years). A Cox proportional haz-
ards model was performed to examine multiple predictors of
time to first MCI diagnosis; these predictors were demo-
graphic (age, years of education, race/ethnicity, sex), genetic
(presence of at least one apolipoprotein ε4 [APOE-ε4] al-
lele), membership in the 1992 or 1999 cohort, and baseline
medical/psychiatric (history of stroke, hypertension, diabetes,
heart disease, or psychiatric illness) variables. In these analy-
ses, time to first MCI diagnosis represents the date of pro-
gression from normal status to MCI and was calculated as
the number of days between the initial neuropsychological
evaluation and the neuropsychological evaluation during
which MCI was first diagnosed. For those who did not ex-
perience development of MCI, time was calculated as the
number of days between the initial neuropsychological eval-
uation and the last neuropsychological evaluation. Age-
specific incidence rates of AD were also calculated among
those with and without MCI at baseline. Another Cox pro-
portional hazards model was performed, this time predicting
time to AD diagnosis. In this model, the demographic, ge-
netic, and medical predictors were added as a first set, and
the additional contribution of MCI status at baseline was
tested by including these variables as a second set of predic-
tors. To determine the individual antecedents of progression
to AD, we again used Cox proportional hazards model to
predict time to first diagnosis of AD, with demographic (age,
education, sex, race/ethnicity, 1992/1999 cohort) and medi-
cal/psychiatric (history of hypertension, diabetes, heart dis-
ease, stroke, or psychiatric illness) variables entered as a first
step, and then allowing individual components of the MCI
classification at the initial visit to enter the model using a
forward stepwise procedure. We performed univariate analy-
ses of variance (examining any significant differences using
Tukey’s post hoc tests) and 2 analyses to compare the char-
acteristics of participants with MCI at baseline who reverted
to normal at follow-up versus those who remained classified
as MCI or progressed to AD. We also calculated the sensi-
tivity, specificity, and accuracy of MCI or AD using the
postmortem diagnosis as the gold standard. The pathological
diagnosis of AD was made if the neuropathologist found suf-
ficient AD changes in the brain.46,47 In some cases, AD
changes were present but were infrequent and did not cross
the standard threshold for neuropathological diagnosis of
AD. We evaluated the sensitivity and specificity of three clin-
ical states for neuropathological diagnosis of AD: (1) diagno-
sis of prevalent MCI or incident MCI or incident AD with-
out reversion to normal at follow-up, (2) prevalent or
incident impairment in any neuropsychological domain (re-
gardless of AD or MCI diagnosis) without reversion to nor-
mal at follow-up, and (3) prevalent or incident neuropsycho-
logical impairment in memory (regardless of AD or MCI
diagnosis) that did not revert to normal at follow-up.
Role of the Funding Source
The funding source had no role in study design, in the col-
lection, analysis, and interpretation of data, or in the writing
of this manuscript. The corresponding authors had full ac-
cess to all the data in the study and had final responsibility
for the decision to submit for publication.
Results
Sample Characteristics
The mean age of the 2,364 participants was 76.1 years
(SD, 6.2 years), and they had an average of 10.0 years
(SD, 4.8) of education. The cohort was 28.4% non-
Hispanic white, 32.6% non-Hispanic black, and
39.0% Hispanic; 68.6% were women. Only 8% of the
Hispanic subjects were interviewed and tested in En-
glish. Information for the Disability and Functional
Limitations scale was primarily provided by the partic-
ipant (97%). The functional instrument used primarily
information from an informant among the remaining
3% of the sample; this small group of elders was sig-
nificantly more likely to have significant functional
complaints and memory complaints, and was more
likely to be classified as having MCI. Informants were
present (but may not have been the primary source for
the Disability and Functional Limitations instrument)
during the initial interview for 6.7% of the partici-
pants, and over the course of all visits, an informant
was present for 18% of the participants. APOE geno-
type was available for 2,067 subjects (87%) in the co-
hort. At the initial visit, 74.2% of the participants re-
ported a history of hypertension, 36.3% heart disease,
23.1% diabetes, and 8.7% a history of stroke. An av-
erage of 2.3 follow-up evaluations was performed with
a mean duration of follow-up of 4.7 years (SD, 2.8).
There were no differences in the initial age of partici-
pants across the 1992 and 1999 cohorts. Compared
with the 1992 cohort, education (in years) was higher
in the 1999 cohort (8.6 vs 10.9 years; t[2,362]  11.9;
p  0.001). There were more Hispanic subjects in the
1992 cohort (47.3%) than the 1999 cohort (33.4%),
and fewer non-Hispanic white subjects (20.3%) in the
1992 cohort compared with the 1999 cohort (33.8%).
Participants in the 1999 cohort were more likely to
report stroke (9.8%) and heart disease (39.2%) than
the 1992 cohort (7.1 and 32.1%, respectively), but the
prevalence of hypertension and diabetes was similar.
The prevalence of MCI at first visit was greater in the
1992 cohort (26.9%) than in the 1999 cohort (21.8%;
2 (1, n  2,364)  7.9; p  0.005). The length of
follow-up was twice as long, on average, among the
1992 cohort (6.7 years) versus the 1999 cohort (3.3
years).
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Incidence Rates for Mild Cognitive Impairment
Over 7,504.9 person-years of follow-up, there were
379 incident MCI cases (Table 1). Table 2 compares
the incidence rates of the 170 cases (2.3%; 95% CI,
1.9–2.6%) in which memory was impaired (MCI-
amnestic and MCI-MCDM combined) and 209 cases
(2.8%; 95% CI, 2.4–3.2%) in which memory was not
impaired (MCI-executive, MCI-visuospatial, MCI-
language, and MCI-MCDN combined) by age, years
of school, race/ethnicity, and sex. The annual incidence
rate of MCI-amnestic (1.4%) was significantly greater
than that of MCI-MCDM (0.87%; incidence rate dif-
ference  0.53%; 95% CI, 0.19–0.87%). A Cox pro-
portional hazards model with time to first diagnosis of
MCI (regardless of the subtype) as the outcome dem-
onstrated that as compared with those aged 65 to 69
Table 1. Incident Cases of Mild Cognitive Impairment among Nondemented Elder Subjects Who Did Not Have











MCI with memory impairment 170 2.3% 1.9% 2.6%
MCI-amnestic 105 1.4% 1.1% 1.7%
MCD with memory 65 0.9% 0.7% 1.1%
MCI without memory impairment 209 2.8% 2.4% 3.2%
MCI-executive 19 0.3% 0.1% 0.4%
MCI-language 67 0.9% 0.7% 1.1%
MCI-visuospatial 85 1.1% 0.9% 1.4%
MCD without memory 38 0.5% 0.1% 0.7%
All MCI subtypes 379 5.1% 4.6% 5.6%
MCI  mild cognitive impairment; CI  confidence interval; MCD  multiple cognitive domains.
Table 2. Rate of Progression to Mild Cognitive Impairment (Memory and Nonmemory Impairment Types) per
100 Person-years (95% Confidence Interval) according to Age, Education, Ethnicity, and Sex among Elders Who
















65–69 261 1,277.3 14 1.1% (0.5–1.7) 22 1.7% (1.0–2.4)
70–74 588 2,588.1 55 2.1% (1.6–2.7) 67 2.6% (2.0–3.2)
75–79 478 1,968.6 44 2.2% (1.6–2.9) 67 3.4% (2.6–4.2)
80 473 1,674.8 57 3.4% (2.5–4.3) 53 3.2% (2.3–4.0)
Education, yr
0–11 1,231 3,741.5 94 2.5% (2.0–3.0) 130 3.5% (2.9–4.1)
12 1,133 3,767.2 76 2.0% (1.6–2.5) 79 2.1% (1.6–2.6)
Ethnicity
White 671 2,140.6 38 1.8% (1.2–2.3) 41 1.9% (1.3–2.5)
Black 771 2,470.8 57 2.3% (1.7–2.9) 72 2.9% (2.3–3.6)
Hispanic 922 2,897.3 75 2.6% (2.0–3.2) 96 3.3% (2.7–4.0)
Sex
Male 743 2,253.6 53 2.4% (1.7–3.0) 62 2.8% (2.1–3.4)
Female 1,621 5,255.1 117 2.2% (1.8–2.6) 147 2.8% (2.4–3.2)
MCI  mild cognitive impairment; CI  confidence interval.
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years, those aged 70 to 74 years (relative risk [RR], 1.6;
95% CI, 1.1–2.4), 75 to 79 years (RR, 1.9; 95% CI,
1.3–2.8), and 80 years and older (RR, 2.5; 95% CI,
1.7–3.6) were at greater risk for development of MCI.
As compared with non-Hispanic white subjects, older
adults who self-identified as black (RR, 1.4; 95% CI,
1.0–1.8) or Hispanic (RR, 1.4; 95% CI, 1.0–1.9)
were also at greater risk for development of MCI. El-
ders with a history of a diagnosis of hypertension were
also at greater risk for development of MCI (RR, 1.4;
95% CI, 1.1–1.9). In this model, sex, education, co-
hort, history of heart disease, diabetes stroke, and psy-
chiatric illness were not significant predictors of inci-
dent MCI. Among the smaller subsample of 1,572
participants with APOE data and without MCI at the
initial visit, older age and hypertension remained risks
for incident MCI, but race/ethnicity was no longer a
significant predictor of progression to MCI. Presence
of the APOE-ε4 allele was not associated with greater
risk for development of MCI. We also performed Cox
proportional hazards models with time to first diagno-
sis of MCI with memory impairment (MCI-amnestic
and MCI-MCDM combined) and MCI without mem-
ory impairment in the entire sample of people without
MCI at the initial visit (n  1,800). Older age and
hypertension increased risk for development of MCI
with memory impairment, whereas heart disease was
protective (RR, 0.70; 95% CI, 0.50–0.98). Fewer than
12 years of education was the only significant risk fac-
tor for development of incident MCI without memory
impairment (RR, 1.4; 95% CI, 1.0–1.9).
Incidence Rate of Alzheimer’s Disease and Dementia
among Subjects with and without Mild
Cognitive Impairment
Over 10,517.4 person-years of follow-up, there were
309 cases of incident AD. As shown in Table 3, the
incidence rates for AD differed by the presence of
MCI. Whereas 10.3% (186/1,800 subjects) without
MCI at their initial visit were diagnosed with AD at a
follow-up visit, 21.8% (123/564 cases) with MCI at
the first visit were diagnosed with AD at follow-up.
Using a Cox proportional hazards model predicting
time to first diagnosis of AD among the entire sample
of 2,364 elders, we found that older participants with
fewer than 12 years of school, black and Hispanic sub-
jects, and those with history of diabetes or stroke were
at greater risk for development of AD. With all demo-
graphic, medical, and psychiatric variables in the
model, we found that those with MCI-MCDM, MCI-
amnestic, MCI-language, and MCI-MCDN initially
were more likely to experience development of AD as
compared with elderly individuals without MCI. Table
4 shows RR of developing AD among MCI subtypes as
determined by a Cox proportional hazards model
among the subset of 2,067 subjects with APOE geno-
Table 3. Rate of Progression to Alzheimer’s Disease per 100 Person-years (95% Confidence Interval) according to










No MCI 1,800 8,224.1 186 2.3% (1.9–2.6)
Age 65–69 yr 261 1,359.1 3 0.2% (0.0–0.4)
Age 70–74 yr 588 2,921.1 37 1.3% (0.9–1.7)
Age 75–79 yr 478 2,178.6 53 2.4% (1.8–3.1)
Age 80 yr 473 1,765.3 93 5.3% (4.2–6.3)
MCI with memory impairment 318 875.5 65 7.4% (5.7–9.2)
Age 65–69 yr 26 126.2 4 3.2% (0.1–6.2)
Age 70–74 yr 73 286.6 13 4.5% (2.1–6.9)
Age 75–79 yr 70 227.9 22 9.7% (5.8–13.5)
Age 80 yr 77 234.7 26 11.1% (7.1–15.1)
MCI without memory impairment 246 1,417.9 58 4.1% (3.1–5.10)
Age 65–69 yr 47 225.0 5 2.2% (0.3–4.2)
Age 70–74 yr 91 417.3 12 2.9% (1.3–4.5)
Age 75–79 yr 90 410.6 20 4.9% (2.8–7.0)
Age 80 yr 90 365.0 21 5.8% (3.4–8.1)
AD  Alzheimer’s disease; CI  confidence interval; MCI  mild cognitive impairment.
500 Annals of Neurology Vol 63 No 4 April 2008
types. These results were essentially identical to that
with the entire sample. Not shown in Table 4 is that as
compared with those aged 65 to 69 years, those aged
70 to 74 years (RR, 2.6; 95% CI, 1.4–4.8), 75 to 79
years (RR, 5.0; 95% CI, 2.7–9.3), and 80 years and
older (RR, 11.2; 95% CI, 6.0–20.1) were at greater
risk for development of MCI. Participants with less
than 12 years of education were 2.0 times (95% CI,
1.4–2.7) more likely to experience development of AD
than those with 12 or more years of education. As
compared with non-Hispanic white individuals, older
adults who self-identified as black (RR, 2.3; 95% CI,
1.5–3.5) or Hispanic (RR, 2.4; 95% CI, 1.6–3.7) were
at greater risk for development of AD, as were those
with an APOE-ε4 allele (RR, 1.4; 95% CI, 1.0–1.7)
and history of diabetes (RR, 1.5; 95% CI, 1.1–1.9)
and stroke (RR, 2.3; 95% CI, 1.6–3.3). Sex, cohort,
hypertension, heart disease, and psychiatric history did
not significantly influence risk for development of AD.
Figure 2 demonstrates the cumulative hazard of devel-
opment of AD among the MCI subtypes among par-
ticipants with APOE-ε4 information. Finally, there
were 18 incident cases of non-AD dementia (5 vascular
dementia, 2 diffuse Lewy body disease, 2 tumor re-
lated, 1 alcohol related, 1 secondary to metabolic dys-
function, 1 secondary to a psychiatric syndrome, and 6
where the cause of dementia could not be determined).
There was no change in the results when time to first
“all-cause” dementia diagnosis was used as the outcome
in these analyses.
Antecedents of Progression to Alzheimer’s Disease
from Mild Cognitive Impairment
Characteristics of the initial assessment were evaluated
as predictors of progression to AD. Adjusting for dif-
ferences in demographics and medical factors, impair-
ment on the memory composite score was the best pre-
dictor of progression to AD from MCI (RR, 3.00;
95% CI, 2.32–3.86), followed by isolated impairment
in language (RR, 2.09; 95% CI, 1.61–2.71). Memory
complaints entered the model as well (RR, 1.66; 95%
CI, 1.23–2.24), as did isolated impairment in visuospa-
tial function (RR, 1.49; 95% CI, 1.14–1.94). These
results did not change in the smaller sample when
APOE-ε4 status was included in the first set of vari-
ables.
Reversal of Mild Cognitive Impairment
All follow-up visits of the 564 elderly subjects with
MCI at the beginning of the study were examined. We
found that 30.2% (n  170) did not have MCI or
dementia at any follow-up visit. About half of those
with MCI initially (n  264; 46.8%) still had MCI at
a subsequent visit and did not revert to normal or
progress to dementia.
Individuals with MCI at baseline who progressed to
AD were older, less well educated, more likely to be
Hispanic, and reported a history of stroke as compared
with both of the groups that did not progress to de-
mentia (Table 5). Those with MCI initially who re-
verted to normal at follow-up did not differ in age,
years of school, sex, race/ethnicity, or presence of med-
ical conditions or an APOE-ε4 allele from elderly sub-
jects diagnosed with MCI at follow-up. Those without
MCI or dementia at any follow-up visit were followed
up for less time (3.4 years, an average of 1.7 visits)
compared with those with MCI (4.7 years, an average
of 2.3 visits) or dementia (5.8 years, an average of 2.9
visits) at follow-up.
To determine whether our results were an artifact of
length of follow-up, we limited the analyses to one
follow-up only. At the first follow-up of the 564 el-
derly subjects with MCI at first visit, 45.2% (n  255)
did not have MCI or dementia, 40.8% (n  230) still
had MCI, 12.8% (n  72) progressed to AD, and
1.2% (n  7) progressed to non-AD dementia. Com-
parisons of background and medical variables among
these groups demonstrated that subjects with MCI ini-
tially who progressed to AD at the next visit were
older, less well educated, and more likely to report a
history of stroke as compared with both of the groups
that did not progress, despite having equal years of
follow-up. There were no significant differences be-
tween the consistent MCI group and the MCI-to-non-
MCI group. Of those with MCI who reverted to nor-
mal, 21% no longer met functional complaint criteria,
35% no longer had memory complaints, and 67% no
Table 4. Relative Risk of Incident Alzheimer’s











MCI-amnestic 3.2 2.1 4.7
MCI-executive 0.7 0.2 2.8
MCI-language 2.0 1.1 3.5
MCI-visuospatial 1.2 0.7 2.0
MCI-MCDM 4.3 2.9 6.4
MCI-MCDN 1.9 1.1 3.0
Other predictors in the Cox proportional hazards model
predicting time to first diagnosis of Alzheimer’s disease (AD)
were age, years of school, sex, race/ethnicity, cohort (1992 vs
1999), presence of hypertension, diabetes, heart disease, stroke,
and psychiatric history.
MCI  mild cognitive impairment; CI  confidence interval;
MCDM  multiple cognitive domains with memory
impairment; MCDN  multiple cognitive domains without
memory impairment.
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longer met the neuropsychological criteria at follow-up.
There was considerable overlap, such that 48% re-
verted because they failed to meet cognitive criteria
only, 12% because of functional criteria only, and 17%
because of memory complaint criteria only, and the re-
mainder reverted because they failed to meet multiple
criteria. The most frequent cause of reversion was no
longer meeting cognitive criteria.
We sought to determine whether there were differ-
ences in those who reverted to normal within each spe-
cific MCI subtype. Surveying all available follow-up
visits, elderly subjects with MCI with isolated impair-
ment in one cognitive domain only were the most
likely to revert to normal at follow-up (38.0% as a
group), whereas those with MCI with impairment in
multiple cognitive domains were least likely to revert to
normal (19.3%; 2 (1 [n  557]  22.2; p  0.001;
Table 6) Reversion to normal among those with cog-
nitive impairment in multiple cognitive domains in-
cluding memory did not differ statistically from the
proportion reverting to normal with cognitive impair-
ment in multiple nonmemory domains. There was no
difference in the proportion of elders with isolated cog-
nitive impairment in memory, executive function,
visuospatial skill, and language reverting to normal at
follow-up.
Validity of Antemortem Diagnosis
Autopsies were obtained in a subsample (n  27) that
was 67% women, had a mean age of 79.3 years (SD,
6.8) at the initial visit, and a mean education of 12.5
years (SD, 4.7). This subsample was 41% non-
Hispanic white, 37% non-Hispanic black, and 22%
Table 5. Demographic and Medical Characteristics of Elderly Subjects with Mild Cognitive Impairment at Baseline
(n  564) by Diagnostic Outcome, Surveying All Follow-up Visits and Only First Follow-up Visit















n 170 264 123 255 230 72
Mean age, yr 76.3 75.8 78.3 76.5 75.8 79.0
Mean education, yr 9.2 9.8 6.9 8.9 9.6 7.0
Black, % 28.2 32.6 24.4 28.2 32.2 25.0
Hispanic, % 43.5 37.9 58.5 42.0 38.0 40.1
Women, % 68.8 68.2 66.7 71.0 63.9 70.8
Apolipoprotein ε4
allele, %
28.1 29.3 28.6 29.6 28.1 27.9
Stroke, % 8.2 6.8 12.2 6.7 7.8 16.7
Hypertension, % 70.6 80.3 78.9 74.5 79.6 77.8
Diabetes, % 20.6 24.6 27.6 21.6 23.9 33.3
Heart disease, % 31.2 35.6 41.5 34.9 33.5 44.4
Average years of
follow-up
3.4 4.7 5.8 2.2 2.2 2.2
Average number of
follow-up evaluations
1.7 2.3 2.9 255 230 72
Data on seven elderly subjects with mild cognitive impairment (MCI) at baseline who progressed to non–Alzheimer’s disease (AD)
dementia are not included.
Fig 2. Cumulative hazard of development of Alzheimer’s dis-
ease (AD) by mild cognitive impairment (MCI) subtype
among 2,364 elderly subjects without dementia at initial visit
and at least one follow-up visit. Dark blue line indicates no
MCI; green line indicates amnestic impairment; gray line in-
dicates executive impairment; purple line indicates language
impairment; yellow line indicates visuospatial impairment; red
line indicates multiple cognitive domains with memory im-
pairment; light blue line indicates multiple cognitive domains
without memory impairment.
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Hispanic. Prevalence of hypertension was 63%, diabe-
tes was present in 29.6%, and 2 individuals (7.4%)
reported clinical stroke. The mean interval between last
clinical evaluation and death was 24.8 months (SD,
21.3).
Specificity was acceptable (94%) for neuropatholog-
ical AD for those diagnosed with prevalent or incident
MCI (all subtypes) or incident AD without reversion
to normal status, but sensitivity was relatively low
(60%). Sensitivity was the same (60%) when the clin-
ical marker was stable neuropsychological impairment
in any cognitive domain (regardless of MCI or AD sta-
tus), but specificity was poor (59%). Memory com-
plaints had a sensitivity of 70% for AD pathology but
poor specificity (35%). Presence of stable neuropsycho-
logical impairment in any cognitive domain had per-
fect specificity (100%) for any brain pathology (not
limited to AD), but sensitivity was low (62%). Three
of the 27 subjects showed reversion of an MCI diag-
nosis to normal cognitive status; 2 of these subjects had
no detectable abnormality in brain tissue, and 1 had an
asymptomatic infarct. False-negative findings included
subjects with combined pathology or AD pathology
alone. False-positive findings included primarily in-
farcts or vascular dementia, but also subjects with lobar
atrophy, Parkinson’s disease, or brain tissue without
recognized abnormality. Among those with AD pathol-
ogy, time between last clinical evaluation was almost
twice as long if clinical diagnosis did not include MCI
or AD (34.7 months; SD,  31.4) as compared with
those with a premortem diagnosis of AD or MCI (18.8
months; SD, 11.1), but this difference did not reach
statistical significance.
Discussion
This investigation describes the incidence rate of MCI
and the progression of MCI to AD in a large
population-based group of elderly adults from diverse
ethnic, linguistic, and educational backgrounds. We
found that elder subjects without MCI at the first visit
who were older than 70 years and had hypertension
were at greater risk for development of MCI. Our AD
progression rates among those with MCI at first visit
are comparable with other longitudinal studies of
aging in white, non-Hispanic, well-educated partici-
pants7,8,11,13,48,49 and black individuals in Indiana.14
We also found that elders with MCI were at greater
risk for development of AD at follow-up, and that
MCI subtypes that included memory impairment are
at the greatest risk for AD. We found that partici-
pants classified as MCI were not always classified as
MCI at follow-up, especially if impairment at first
visit was limited to one isolated cognitive domain.
Twenty-seven cases underwent autopsy, which dem-
onstrated that antemortem diagnosis of consistent
MCI (ie, MCI that did not revert to normal over
time) or incident AD had a 60% sensitivity and 94%
specificity for AD at postmortem examination.
We also compared the incidence rates of MCI sub-
types. Over an average follow-up of 4.7 years, inci-
dence of amnestic MCI, MCI-visuospatial, and MCI-
language were highest, whereas incidence of isolated
MCI-executive was lowest. There are few epidemiolog-
ical studies of MCI incidence. Because the mean age of
the cohort, the length of follow-up, and the criteria
used for MCI differ across studies,11 it is difficult to
compare incidence rates in this study with other stud-
ies. Nevertheless, it appears that our incidence rates of
MCI with memory impairment (2.3% annual inci-
dence rate) are greater than studies conducted in Ger-
many,50 France,49 or the United States,11 but compa-
rable with the Italian Longitudinal Study on Aging.8
Being older than 75 years was the most powerful
predictor of progression from MCI to AD. However,
Table 6. Diagnostic Outcomes of Elders with Mild Cognitive Impairment at Baseline by Mild Cognitive
Impairment Subtype, Surveying All Follow-up Visits
MCI Subtype
MCI to No MCI MCI to MCI MCI to AD
n % n % n %
MCI-amnestic 44 35.5 51 41.1 29 23.4
MCI-executive 20 44.4 23 51.1 2 4.4
MCI-language 24 34.8 28 40.6 17 24.6
MCI-visuospatial 39 40.6 39 40.6 18 18.8
MCI-MCD with memory impairment 22 18.5 61 51.3 36 30.3
MCI-MCD with memory impairment 21 20.2 62 59.6 21 20.2
MCI with memory impairment 66 27.2 112 46.1 65 26.7
MCI without memory impairment 104 33.1 152 48.4 58 18.5
Data on seven elderly subjects with mild cognitive impairment (MCI) at baseline who progressed to non–Alzheimer’s disease (AD)
dementia are not included.
MCD  multiple cognitive domains.
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MCI status at first visit was also useful in predicting
who would go on to experience development of AD.
Elderly subjects with MCI-MCDM had the greatest
progression rates and were about 4.3 times as likely to
develop AD at follow-up as compared with elderly sub-
jects without MCI. Furthermore, compared with elders
without MCI, we found that those with amnestic
MCI, MCI-language, and MCI-MCDN were at
greater risk for development of AD at follow-up, but
those with MCI-visuospatial and MCI-executive were
not. Because progression to AD was less likely among
those with MCI-visuospatial and MCI-executive, this
suggests that elders in these categories are less likely to
have underlying AD pathology. Therefore, our evalua-
tion of incidence and antecedents of progression to
MCI-visuospatial and MCI-executive is less meaningful
than the analyses among elders with amnestic MCI,
MCI-language, and MCI-MCDN. Evaluation of lon-
gitudinal outcomes of different subtypes of MCI can
help guide future research to focus on those subtypes
that are most likely to progress to AD. It follows that
early biomarkers of risk for AD such as plasma A,
insulin levels, or volume of the hippocampus should
show differences from healthy control subjects among
elders classified as having amnestic MCI, MCI-
language, and MCI-MCDN.
We found that medical history of hypertension was
associated with MCI, whereas history of diabetes and
stroke were risk factors for development of AD. Pos-
session of at least one APOE-ε4 allele did not predict
progression to MCI, and although significant,
APOE-ε4 genotype was a weaker predictor of progres-
sion to AD than MCI with memory impairment. This
finding may relate to the relatively old age of this co-
hort. Because examination of the relation of these vari-
ables to MCI classification was exploratory, further
study is needed to determine the cardiovascular and ge-
netic correlates of different MCI subtypes and their in-
teraction with memory function on risk for dementia.
In this study, black and Hispanic subjects, and those
with less than a high school education, were not at
greater risk for development of MCI; however, these
groups were at greater risk for development of AD even
when MCI status at initial visit was taken into account.
This finding is likely related to the fact that our neu-
ropsychological criteria for MCI used years of educa-
tion and norms that were appropriate for the ethnic
groups included in the study.
Examination of “reversion to normal” among sub-
jects with MCI was emphasized in this study. If as-
sessed over the course of the entire follow-up period,
30.2% of our subjects with MCI at their initial visit
were not classified as MCI or demented subsequently.
This proportion is comparable with other epidemiolog-
ical studies, where 14 to 44%7,11,14 of those with MCI
at first visit did not have MCI at follow-up. Although
we did not find any demographic or medical factors
that were associated with instability of diagnosis, we
found that MCI with impairment in multiple cognitive
domains, with or without memory impairment, was
less likely to revert to normal than MCI with impair-
ment in one cognitive domain. This is not surprising
because elders with impairment in multiple cognitive
domains have poorer overall cognitive function, and
thus their neuropsychological test scores are less likely
to be on the border of the cutoff. Of those who re-
verted to normal, most reverted because of cognitive
criteria only, with relatively smaller proportions revert-
ing because of functional criteria or memory complaint
criteria only. If the cognitive criteria for MCI involve a
single “cutoff” of any kind, it is possible that normal
variability in cognitive test performance may lead to
changes in classification. “Reversions” of this type may
not actually represent transitions of one clinical state to
another. Continued follow-up of elders who revert to
normal should demonstrate whether these individuals
are in early stages of dementia (and therefore cognitive
function may be expected to show mild fluctuation),
whether fluctuation is inherent throughout the course
of their follow-up, or whether fluctuation is a marker
for “misdiagnosis” of cerebrovascular disease or normal
age-related brain changes. We have preliminary support
for the latter from our autopsy sample, in which none
of the participants who reverted to normal after receiv-
ing a diagnosis of MCI was found to have AD at post-
mortem examination.
Compared with other clinicopathological studies,51
the sensitivity of antemortem MCI and incident AD
diagnoses to AD pathology was relatively poor. We
suspect this is at least partially explained by the fact
that among those with neuropathological AD, the
length time between last study visit and death was
twice as long in those who were not diagnosed with
AD or MCI clinically as compared with those who
were. All of the autopsied elderly cases in our study
who were diagnosed with incident AD were classified
as having MCI either at their first visit or a subsequent
visit before their AD diagnosis. Specificity was high.
Although the autopsy sample was comparable with the
overall group with respect to age at baseline, sex, years
of education, and ethnic group, a much larger cohort
with autopsy is needed before drawing sweeping con-
clusions about the accuracy of MCI diagnosis with re-
spect to neuropathology.
A limitation of this study is that our average
follow-up is only 4.7 years. With longer follow-up, we
will be able to compare progression to AD among el-
derly subjects without MCI at the initial visit who do
and do not transition to MCI within the course of the
study. Furthermore, it is possible that our conclusions
about reversion to normal status after an initial classi-
fication as MCI would change with a longer follow-up
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period. It is also possible that those who died before we
were able to complete the next follow-up experienced
development of MCI or dementia before their death;
however, our data do not allow us to estimate the pro-
portion of elderly subjects who may have progressed.
To address this problem in future studies, when we
discover that a participant has died, we are now admin-
istering the Dementia Questionnaire52,53 to family
members to inquire about cognitive status and func-
tional decline before death.
One other potential limitation is that our cognitive
battery did not include traditional measures of atten-
tion that would be able to distinguish impairment in
this cognitive domain from other domains of cognitive
function. It is likely that attentional processes are in-
volved in performance on most, if not all, of the mea-
sures that were administered. To the extent that flu-
ency, verbal list learning and recall, and nonverbal
memory tap into attentional processes more directly
than measures of drawing, perhaps the cognitive do-
mains of language and memory in this study are more
“attention loaded” than the visuospatial domain.
The utility of the subjective memory complaint cri-
teria for MCI is controversial because some studies
have found that complaints do not improve on the
ability to predict progression to AD.11,12,50 We also
found that when the criteria for MCI were allowed to
predict progression to AD separately, neuropsycholog-
ical impairment in memory conferred a threefold
greater risk and impairment in language a twofold
greater risk for incident AD. Presence of memory com-
plaints and isolated visuospatial impairment reached
statistical significance as a predictor of incident AD,
albeit weaker predictors than memory and language
impairment. Our autopsy data, although from a lim-
ited sample, showed that presence of consistent neuro-
psychological impairment in one or more cognitive do-
mains was just as good a predictor of AD pathology as
meeting full criteria for MCI or AD; that is, in this
limited sample, presence of a memory complaint did
not improve the sensitivity of detection of AD neuro-
pathology. Specificity of neuropsychological impair-
ment was lower than that of MCI and/or AD, but this
might be anticipated given that neuropsychological
function may be affected by any brain disorder, not
just AD. Specificity of neuropsychological impairment
was perfect when the presence of any neuropathology
was the gold standard. Furthermore, information from
our autopsy sample supports the idea that neuropsy-
chological impairment has better overall accuracy for
the presence of AD pathology than presence of mem-
ory complaints, primarily because memory complaints
are so prevalent in this age cohort (67% of our autop-
sied sample had consistent memory complaints), de-
creasing their specificity for AD. These clinical and
neuropathological results suggest that combining objec-
tive neuropsychological test scores and subjective com-
plaint data are useful components of MCI classifica-
tion, but that perhaps neuropsychological criteria
should be given more weight than memory complaints.
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